Who is sponsoring NCT03499626?

NCT03499626 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT03499626?

Interventions in NCT03499626: ASLAN001.

What condition does NCT03499626 study?

NCT03499626 studies Advanced/ Metastatic Hepatocellular Carcinoma.

Is NCT03499626 still recruiting?

NCT03499626 is currently status unknown. Last updated 17 April 2018.

Last reviewed 2018-04-17 · How we verify

NCT03499626

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)

Status unknown Phase 1, PHASE2 Last updated 17 April 2018

What this trial tests

Phase 1, PHASE2 trial testing ASLAN001 in Advanced/ Metastatic Hepatocellular Carcinoma in 22 participants. Status unknown.

Timeline

5 May 2017

Primary endpoint
5 May 2019

5 May 2021

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	5 May 2017
Primary completion	5 May 2019
Estimated completion	5 May 2021
Sites	1 location across Singapore

Drugs / interventions tested

ASLAN001 — full drug profile →

Conditions studied

Advanced/ Metastatic Hepatocellular Carcinoma — all drugs for Advanced/ Metastatic Hepatocellular Carcinoma →

Sponsor

National University Hospital, Singapore

Who can join

Adults 21 to 99, any sex, with Advanced/ Metastatic Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, allocation open label study. Phase 1 is a dose-finding phase in patients with advanced/ metastatic hepatocellular carcinoma (HCC) who have progressed on first line Sorafenib or Lenvatinib. The primary objective of this study will be to establish the maximal tolerable dose (MTD) of ASLAN001 (Varlitinib) in the study population The secondary objectives include: 1. To evaluate the efficacy of ASLAN001 (Varlitinib), as measured by duration of response (DoR), progression free survival (PFS), overall survival (OS) and disease control rate (DCR) 2. To assess the ORR, DoR, PFS, DCR and OS by tumor EGFR/HER2/HER3/HER4 status 3. To identify tumor and host biomarkers predictive of treatment response or toxicity to ASLAN001.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer.
Arienti C, Pignatta S, Tesei A. · · 2019 · cited 97× · PMID 31850207 · DOI 10.3389/fonc.2019.01308
Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529
Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside.
Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. · · 2020 · cited 8× · PMID 31991677 · DOI 10.3390/vaccines8010041
Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact.
Federico P, Giunta EF, Tufo A, Tovoli F, et al · · 2022 · cited 5× · PMID 36551730 · DOI 10.3390/cancers14246245
Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma.
Hao X, Li Z, Su X, Li J, et al · · 2025 · PMID 40851753 · DOI 10.1177/17588359251363102

Verify or expand the search:

Other trials of ASLAN001

Trials testing the same drug.

NCT07166367 — Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer · Phase 2 · terminated
NCT02338245 — Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab · Phase 2 · completed
NCT02648425 — Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine · Phase 1 · completed

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03499626 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 17 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03499626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing